Immunohistochemical expression of E-Cadherin in gastric carcinoma in Erbil city, Kurdistan Region

Ara Azad  Mustafa; Jalal Ali Jalal

doi:10.56056/amj.2022.156

Authors

Ara Azad Mustafa
Jalal Ali Jalal

DOI:

https://doi.org/10.56056/amj.2022.156

Keywords:

Gastric carcinoma, E-Cadherin, Immunoexpression

Abstract

Background and objectives: Gastric carcinoma is at fourth position incidence-wise and holds a second place for deaths due to cancer. The Cadherins represent an important class of the adhesiveness molecules, which play an essential role in the homotypical cell-cell adhesion and in the complex process of invasion and metastasis. The point of this study is to identify the rate of the E-Cadherin immunoexpression in gastric carcinoma in Erbil locality and investigate its association with the clinico-pathological parameters.

Methods: A retrospective study was carried out in Rizgary teaching hospital and private laboratories in Erbil city for the period from Jan.2018 - Jan.2020. A total of 75 formalin fixed, paraffin embedded archival tissue blocks of total or partial gastrectomy samples for gastric carcinoma cases were collected, then E-cadherin immunohistochemistry was tested.

Results: Twenty-one cases (28%) were categorized as high expression for E-Cadherin immunoexpression. At the same time 38 (50.7%) of the cases were classified as low expression and 16 (21.3%) of cases were labelled with no expression. E-Cadherin status was significantly associated with the tumor type and tumor grade, in which high E-Cadherin expression about (61.9%) was demonstrated in intestinal type tumors, (38.1%) in diffuse type tumors and about (57.1%) was performed in well-moderately differentiated tumors and (42.9%) in poorly differentiated tumors. While no significant association was found between E-Cadherin expression and other clinico-pathological parameters.

Conclusions: Our result support the hypothesis that the E-Cadherin immunostain is commonly expressed in Gastric cancer, and it was significantly related with type and grade of the tumor.

Downloads

Download data is not yet available.

References

Cabebe EC, Mehta VK, Fisher G. Gastric cancer, eMedicine Specialties, Oncology, Carcinomas of the Gastrointestinal Tract, 2010.Available from: http://www.emedicine.medscape.com /article/278744.

Carl-McGrath S, Ebert M, Röcken Ch. Gastric adenocarcinoma: epidemiology, pathology and pathogenesis, Cancer Therapy, 2007;5:877–94.

Lauren P. The two histological main types of gastric carcinoma: Diffuse and so-called intestinal type carcinoma. An attempt at histo-clinical classification, Acta Pathol Microbiol Scand 1965;64:31–49.

Satoh S, Kawashima K, Matsumoto S, et al. Retrospective evaluation of sequential outpatient chemotherapy for advanced gastric cancer, Chemother 2007;53(3):223–6.

Peek RM Jr, Blaser MJ. Helicobacter pylori and gastrointestinal tract adenocarcinomas, Nat Rev Cancer 2002;2(1):28–37.

Eslick GD, Lim LL, Byles JE, Xia HH, Talley NJ. Association of Helicobacter pylori infection with gastric carcinoma: a meta-analysis. Am J Gastroenterol. 1999;94 (9): 2373-9.

Huang JQ, Sridhar S, Chen Y, Hunt RH. Meta-analysis of the relationship between Helicobacter pylori seropositivity and gastric cancer. Gastroenterology. 1998; 114:1169–79.

Helicobacter and Cancer Collaborative Group. Gastric cancer and Helicobacter pylori: a combined analysis of 12 case control studies nested within prospective cohorts. Gut. 2001; 49:347–53.

Danesh J. Helicobacter pylori infection and gastric cancer: systematic review of the epidemiological studies. Aliment Pharmacol Ther. 1999; 13:851–6.

Charalabopoulos K, Papalimneou V, Evangelou A, et al. Is the E-cadherin downregulation observed in Helicobacter pylori infection associated with gastric cancer development? An additional element in the disease jigsaw, Exp Oncol 2003;25(4):270–3.

Shun CT, Wu MS, Lin MT, Chang MC, Lin JT, Chuang SM. Immunohistochemical evaluation of cadherin and catenin expression in early gastric carcinomas: correlation with clinicopathologic characteristics and Helicobacter pylori infection. Oncol 2001; 60(4):339–45.

Tegtmeyer N, Wessler S, Necchi V et al. Helicobacter pylori Employs a Unique Basolateral Type IV Secretion Mechanism for CagA Delivery. Cell Host & Microbe, 2017; 22 (4): 552-60.

Takeichi M. Morphogenetic roles of classic cadherins. Curr Opin Cell Biol 1995; 7: 619-27

Gumbiner BM. Regulation of cadherin adhesive activity. J Cell Biol 2000; 148: 399-404.

Mareel M, Bracke M, Van Roy F, Invasion promotor versus invasion suppressor molecules: the paradigm of E-cadherin, Mol Biol Rep 1994;19(1):45–67.

Wang Q, Gu D, Wang M, Zhang Z, Tang J, Chen J. The E-cadherin (CDH1) -160C>A polymorphism associated with gastric cancer among Asians but not Europeans. DNA Cell Biol 2011;30(6):395–400.

Christofori G, Semb H. The role of the cell-adhesion molecule E-cadherin as a tumour-suppressor gene Trends. Biochem Sci 1999;24(2):73–6.

Handschuh G, Candidus S, Luber B et al. Tumour-associated E-cadherin mutations alter cellular morphology, decrease cellular adhesion and increase cellular motility. Oncogene 1999;18(30):4301-12.

Almeida PR, Ferreira VA, Santos CC, et al. E-cadherin immunoexpression patterns in the characterisation of gastric carcinoma histotypes, J Clin Pathol 2010;63(7):635–9.

Takeichi M, Cadherins in cancer: implications for invasion and metastasis. Curr Opin Cell Biol 1993;5(5):806–11.

Grunwald GB. The structural and functional analysis of cadherin calcium-dependent cell adhesion molecules. Curr Opin Cell Biol 1993; 5: 797-805

Tackeichi M. Cadherins: a molecular family important in selective cell-cell adhesion. Annue Rev Biochem1990; 59: 237-52.

Amin M, Edge S, Greene F et al. AJCC Cancer Staging Manual. Eighth ed., Springer, New York, 2017.

Chu Y-Q, Ye Z-Y, Tao H-Q et al. Relationship between cell adhesion molecules expression and the biological behavior of gastric carcinoma. World J Gastroenterol. 2008; 14(13): 1990–6. 25. Zhou Y. N., XU C. P., Han B., et al. Expression of E-cadherin and ?-catenin in gastric carcinoma and its correlation with the clinicopathological features and patient survival, World J Gastroenterol, 2002, 8(6):987-93.

Joo Y. E., Park C. S., Kim H. S., et al. Prognostic significance of E-cadherin/catenin complex expression in gastric cancer, J Korean Med Sci, 2000, 15(6):655–66.

Guzman P., Araya J., Villaseca M., et al. Immunohistochemical expression of the E-cadherin–catenin complex in gastric cancer. Rev Med Chil, 2006, 134(8):1002–9.

Wang L., Zhang F., Wu P. et al. Disordered beta-catenin expression and E-cadherin/ CDH1 promoter methylation in gastric carcinoma, World J Gastroenterol, 2006; 12(26):4228–31.

Lazar D, Taban S, Ardeleanu C et al. The immunohistochemical expression of E-cadherin in gastric cancer; correlations with clinicopathological factors and patients’ survival. Rom J Morphol Embryol. 2008;49(4):459-67. 30. Stanculescu D, Margaritescu C, Stepan A, et al. E-cadherin in gastric carcinomas related to histological prognostic parameters, Rom J Morphol Embryol 2011, 52(3):1107-12.

Sridevi C, Pavitra K, Telangana J, et al. Evaluation of e-cadherin expression in gastric cancer as a prognostic marker Received: 2018Mallareddy Medical College for Women, Indian J Pathol Oncol; 6(1), 90-7.